United BioChannels (UBC) is excited to announce that we have partnered with RedShift
BioAnalytics, Inc. to support their commercial expansion activities in characterization of
secondary structure in formulations, and biophysical and structural characterization in process
monitoring, target validation, and drug discovery of new targets based on conformational
change in secondary structure in North America. UBC specializes in the development and
implementation of proven marketing and sales strategies for life science companies and has
built a reputation on enabling novel, impactful technologies to scientists worldwide in areas of
unmet need.

“RedShift BioAnalytics, Inc. innovations in IR spectroscopy have brought characterization of
secondary structural determination into a new era that can be implemented in a simplified and
automated manner in any stage of the formulation process that enables faster and more
informed decisions to be made within early through late stage formulation. We are also excited
to have the ability to work with RedShift BioAnalytics, Inc. to explore new applications in
bioprocessing application, target validation, validation of hits in discovery for undruggable or
challenge targets where subtle changes in conformational change is important to monitor and
results in the discovery of new therapeutics that work through non-traditional drugging
mechanisms.” – Monica Errico, Managing Director of United BioChannels.
“We are very much looking forward to this engagement with UBC to come alongside our own
commercial team and help RedShift address the rapidly growing demand for our novel MMS
technology.” – Julien Bradley, CEO, RedShift BioAnalytics, Inc.

This partnership will enhance RedShift Bio’s leadership position in IR spectroscopy instruments
by business development to expand existing markets as well as explore additional market


About RedShift BioAnalytics, Inc.

RedShift BioAnalytics, Inc. ​is a provider of innovative analytical instrumentation for the
research, development and manufacture of protein therapeutic drugs. The company has
developed a powerful new analytical technique, Microfluidic Modulation Spectroscopy (MMS)
that enables direct probing of the biophysical structure of proteins. The patented MMS
technology provides comprehensive secondary structure information across five key
measurements, in a single automated analysis, replacing the requirement to run samples on
multiple instruments. For further information, please visit​ ​www.redshiftbio.com​ or email

To find out more about RedShiftBio:
Please visit​ ​www.redshiftbio.com/collaboration​, or email ​info@redshiftbio.com